Core Viewpoint - The explosion at Youdao Chemical has led to a significant market reaction, with related companies' stock prices surging and the pesticide sector experiencing a notable increase in value [1] Industry Overview - Chlorantraniliprole is a highly effective, broad-spectrum, low-toxicity insecticide widely used in various crops, and it has become the largest-selling insecticide globally since its launch in 2008 [2] - The domestic production capacity of chlorantraniliprole is approximately 200,000 tons per year, but the actual production last year was less than 6,000 tons, indicating a significant oversupply in the long term [2] - The price of chlorantraniliprole has increased from 210,000 yuan per ton at the beginning of the year to 250,000 yuan per ton following the explosion, reflecting a 10% increase [2] Company Insights - Youdao Chemical, established in August 2019, is a subsidiary of Haomai Group and is the largest producer of chlorantraniliprole with an annual capacity of 11,000 tons [1] - Hongyang currently has a production capacity of 2,000 tons per year for chlorantraniliprole, with an additional 1,000 tons expected to be completed by September [3] - Lier Chemical is optimistic about the market prospects for chlorantraniliprole and is currently constructing a 5,000-ton production facility [3] - The production of chlorantraniliprole is highly dependent on intermediates, and the shutdown of Youdao Chemical may lead to supply tightness for these intermediates, impacting downstream formulation companies [4]

Macro and Strategy - The macroeconomic review indicates that the PMI data for May shows improvement, with the impact of tariffs temporarily alleviated and resilience in the consumer services sector [3][8] - The high-tech manufacturing macro report reveals that the National Securities weekly high-tech manufacturing diffusion index remains flat, indicating mixed performance across various sectors [3][9] - The macroeconomic report highlights weak high-frequency growth indicators, with a rebound in export chains and food prices [10][11] Industry and Company - The investment strategy for the petrochemical industry in June 2025 focuses on potassium fertilizers, allulose, refrigerants, pesticides, and biodiesel as key investment directions [3][26] - The chemical industry report notes a significant increase in air conditioning production in Q2, with prices of third-generation refrigerants continuing to rise [3] - The pharmaceutical industry report from the ASCO annual meeting emphasizes the importance of domestic dual antibodies and ADCs as innovative molecules [3] - The electric power industry report highlights the acceleration of solid-state battery industrialization and steady progress in charging pile construction [3] - The real estate industry report indicates a worsening of losses in the sector, with no significant improvement in fundamentals [3] - The communication industry strategy for June 2025 points to sustained demand for high-speed optical modules and the development of commercial aerospace [3] Fixed Income and REITs - The fixed income strategy for June 2025 anticipates a new round of market activity driven by technological advancements, with a focus on convertible bonds [10][17] - The public REITs report indicates that operational REITs are performing better than property REITs, with a notable increase in quality warehouse assets entering the market [12][14] - The REITs index shows a year-to-date increase of 10.0%, outperforming the Shanghai Composite Index [14][15] ESG Focus - The ESG report highlights significant developments in green finance and carbon market expansion in China, with new policies aimed at promoting sustainable development [18][20] - The ESG product monthly report indicates a notable increase in the issuance of ESG bonds, with fluctuations in the number of public ESG funds [22][23]

Core Viewpoint - The credit rating of Limin Holdings Group Co., Ltd. remains stable at AA, reflecting its strong market position in the pesticide industry and improved financial metrics since 2024 [4][5][9]. Company Overview - Limin Holdings is recognized as one of the key pesticide manufacturers in China, maintaining a high market share in the domestic raw material market with a diverse product structure and strong R&D capabilities [4][9]. - The company has seen a continuous increase in patent authorizations and product registrations, indicating robust innovation [4][15]. Financial Performance - Total assets for Limin Holdings were reported at 70.56 billion yuan in 2022, with total liabilities at 42.16 billion yuan, resulting in a debt-to-asset ratio of 59.75% [6][20]. - The company’s net profit improved significantly from 0.64 billion yuan in 2022 to 2.27 billion yuan in 2022, with a notable increase in operating revenue from 42.24 billion yuan to 50.16 billion yuan [6][17]. - EBITDA increased to 6.12 billion yuan, reflecting improved operational efficiency [7][17]. Market Position and Risks - The company has a strong market presence with a diverse product range, including fungicides, insecticides, herbicides, and veterinary drugs, and has expanded production capacity in recent years [10][11]. - However, the company faces challenges such as fluctuating raw material prices and the need to manage new production capacity effectively [5][9][10]. Investment and R&D - Limin Holdings has maintained a consistent investment in R&D, with expenditures amounting to 2.06 billion yuan in 2022, representing 4.12% of its operating revenue [15][16]. - The company has established multiple R&D platforms and has been collaborating with various biotech firms to develop new agricultural products [15][16]. Future Outlook - The credit outlook for Limin Holdings is stable, with potential for upgrades if capital strength and profitability significantly improve [5][9]. - The company is expected to continue benefiting from favorable market conditions and policy support in the agricultural sector, although it must remain vigilant regarding supply and demand dynamics [9][10].

利民控股集团股份有限公司 2025 年度跟踪评级报告 编号：信评委函字[2025]跟踪 0287 号 利民控股集团股份有限公司 2025 年度跟踪评级报告 声 明 中诚信国际信用评级有限责任公司 2025 年 5 月 29 日 2 本次评级为委托评级，中诚信国际及其评估人员与评级委托方、评级对象不存在任何其他影响本次评级行为独立、 客观、公正的关联关系。 本次评级依据评级对象提供或已经正式对外公布的信息，以及其他根据监管规定收集的信息，中诚信国际按照相关 性、及时性、可靠性的原则对评级信息进行审慎分析，但中诚信国际对于相关信息的合法性、真实性、完整性、准 确性不作任何保证。 中诚信国际及项目人员履行了尽职调查和诚信义务，有充分理由保证本次评级遵循了真实、客观、公正的原则。 评级报告的评级结论是中诚信国际依据合理的内部信用评级标准和方法、评级程序做出的独立判断，未受评级委托 方、评级对象和其他第三方的干预和影响。 本评级报告对评级对象信用状况的任何表述和判断仅作为相关决策参考之用，并不意味着中诚信国际实质性建议任 何使用人据此报告采取投资、借贷等交易行为，也不能作为任何人购买、出售或持有相关金融产品的依据。 中 ...

债券代码：128144 债券简称：利民转债 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、债券代码：128144； 2、债券简称：利民转债； 3、恢复转股时间：自 2025 年 5 月 28 日起恢复转股。 利民控股集团股份有限公司（以下简称"公司"）因实施 2024 年年度权益分派， 根据《利民控股集团股份有限公司公开发行可转换公司债券募集说明书》及相关规 定，公司可转换公司债券（债券简称：利民转债，债券代码：128144）自 2025 年 5 月 19 日起至本次权益分派股权登记日（2025 年 5 月 27 日）止暂停转股。具体内容 详见公司于 2025 年 5 月 16 日披露于《证券时报》《中国证券报》及巨潮资讯网 （www.cninfo.com.cn）上的《公司关于实施权益分派期间利民转债暂停转股的公告》 （公告编号：2025-046）。 根据规定，"利民转债"将于本次权益分派股权登记日后的第一个交易日，即 2025 年 5 月 28 日起恢复转股。敬请公司可转换公司债券持有人留意！ 股票代码：002734 股票简称：利民股份 公 ...

Group 1 - The report highlights that Alibaba Health achieved a revenue of 30.6 billion yuan in FY2025, representing a 13% year-on-year growth, and a net profit of 1.4 billion yuan, which is a 62% increase year-on-year [3][4] - The medical e-commerce platform business saw a robust growth of 54% year-on-year, reaching 3.6 billion yuan, driven by stable GMV growth and the inclusion of marketing and value-added services [4] - The self-operated pharmaceutical business also grew by 10% year-on-year to 26.1 billion yuan, supported by an increase in active consumers and ARPU [4][5] Group 2 - The report indicates that the AIDC business has a promising outlook, with the global power quality governance market expected to grow from 38.6 billion USD in 2024 to 56.3 billion USD by 2030 [8] - The demand for power quality governance is driven by sectors sensitive to power quality, such as semiconductor manufacturing and data centers, with the low-voltage power quality governance equipment market projected to grow significantly [8][9] - The company is positioned as a leader in the domestic power quality equipment market, benefiting from the construction boom in data centers [9] Group 3 - The report notes that Guangxin Co. experienced a 20.9% decline in revenue to 4.64 billion yuan in 2024, primarily due to falling pesticide prices and increased competition [13] - The company’s pesticide segment revenue dropped by 17% year-on-year, while the intermediate products segment saw a 25% decline [13][14] - The report anticipates a recovery in pesticide demand, with projected revenues of 4.8 billion, 5.8 billion, and 6.9 billion yuan for 2025, 2026, and 2027 respectively [14][22] Group 4 - The report discusses the potential bankruptcy of Monsanto, which could benefit domestic glyphosate and glyphosate ammonium producers, as it holds a 32% global market share [17][18] - Glyphosate prices have stabilized, with a reported price of 23,200 yuan per ton, indicating a potential turning point for the industry [19][20] - The report suggests that the domestic glyphosate and glyphosate ammonium companies may see increased demand due to the competitive landscape shifting [22][23] Group 5 - The report indicates that Tongkun Co. achieved a revenue of 101.3 billion yuan in 2024, a 22.6% increase year-on-year, with a net profit of 1.202 billion yuan, reflecting a 50.8% growth [26][28] - The company’s polyester filament sales increased, supported by limited new capacity in the industry and growing downstream demand [26][27] - Future revenue projections for Tongkun are set at 101.3 billion, 105.3 billion, and 111.3 billion yuan for 2025, 2026, and 2027 respectively, with a corresponding net profit forecast of 2.233 billion, 3.129 billion, and 3.973 billion yuan [30]

1、根据《中华人民共和国公司法》《上市公司股份回购规则》《深圳证券交 易所上市公司自律监管指引第 9 号——回购股份》等相关规定，上市公司回购专用 账户中的股份不享有利润分配等权利。截至披露日，利民控股集团股份有限公司（以 下简称"公司"或"本公司"）通过回购专用证券账户持有公司股份 4,216,110 股， 因此公司以本次权益分派实施时股权登记日的公司总股本减去公司回购专户股份 后的股本为基数，向全体股东每 10 股派发现金红利 2.50 元（含税），不送红股， 不以公积金转增股本。公司本次实际现金分红总额=实际参与权益分派的股本×分 配比例，即:417,023,461 股×0.25 元/股=104,255,865.25 元。 2、因公司回购专户上的股份不享有利润分配的权利，根据股票市值不变原则， 实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比例将减 小，本次权益分派实施后计算除权除息价格时，按总股本折算每股现金红利=现金 分红总额/公司总股本=104,255,865.25 元/421,239,571 股=0.2474977 元/股（保留 到小数点后七位，最后一位直接截取，不四舍五入）。本 ...

股票代码：002734 股票简称：利民股份 公告编号：2025-048 利民控股集团股份有限公司 关于可转换公司债券转股价格调整的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 利民控股集团股份有限公司（以下简称"公司"）公开发行了 980 万张可转换 公司债券（债券简称：利民转债，债券代码：128144）并于 2021 年 3 月 24 日上市。 根据《公司公开发行可转换公司债券募集说明书》及中国证券监督管理委员会（以 下简称"中国证监会"）关于可转换公司债券发行的有关规定，在本次可转债发行 之后，当公司因派送股票股利、转增股本、增发新股（不包括因本次可转债转股而 增加的股本）、配股使公司股份发生变化及派送现金股利等情况时，将按下述公式 进行转股价格的调整（保留小数点后两位，最后一位四舍五入）： 派送股票股利或转增股本：P1=P0/（1+n） 增发新股或配股：P1=（P0+A×k）/（1+k） 上述两项同时进行：P1=（P0+A×k）/（1+n+k） 派送现金股利：P1=P0－D 上述三项同时进 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、债券代码：128144； 2、债券简称：利民转债； 3、转股起止时间：2021 年 9 月 6 日至 2027 年 2 月 28 日； | 股票代码：002734 | 股票简称：利民股份 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：128144 | 债券简称：利民转债 | | 利民控股集团股份有限公司 关于实施权益分派期间利民转债暂停转股的公告 利民控股集团股份有限公司（以下简称"公司"）将于近日实施 2024 年年度权 益分派，根据《利民控股集团股份有限公司公开发行可转换公司债券募集说明书》 第二节中"转股价格的调整方式及计算公式"相关条款的规定，自 2025 年 5 月 19 日起至本次权益分派股权登记日止，公司可转换公司债券（债券简称：利民转债， 债券代码：128144）将暂停转股，本次权益分派股权登记日后的第一个交易日起恢 复转股。 在上述期间，公司可转换公司债券正常交易，敬请公司可转换公司债券持有人 注意。 特此公告。 利民控股集团股份有限公 ...

Core Insights - The article discusses the increasing demand for the fungicide Bacillus thuringiensis (also known as 2,4,5,6-tetrachloro-1,3-benzodioxole), driven by factors such as the outbreak of soybean rust in Brazil, the growing need for global disease resistance management, and the expansion of crop planting areas in emerging markets like China, India, and Southeast Asia [1][8][10]. Industry Overview - Bacillus thuringiensis is a broad-spectrum protective fungicide with advantages such as high efficiency, low toxicity, broad-spectrum activity, low residue, and long efficacy period [1][8]. - The global demand for Bacillus thuringiensis has increased from 20,000 tons in 2012 to over 60,000 tons in 2024, with projections to reach 72,000 tons by 2025 [1][8]. - The production supply of Bacillus thuringiensis is tightening due to strict environmental policies and limited new production capacity, leading to a continuous increase in market prices [8][10]. Application Demand - Bacillus thuringiensis is widely used in agriculture and forestry for the prevention of fungal diseases, particularly in vegetables and fruits, and is also utilized in non-agricultural areas such as golf courses and ornamental plants [6][8]. - The application demand breakdown shows that 30.45% is in vegetable cultivation, 27.36% in peanuts and grains, 29.36% in fruit cultivation, and 6.22% in other non-agricultural areas [6]. Market Dynamics - The market for Bacillus thuringiensis is highly concentrated, with major production capacities located in China, where leading companies include Zhejiang Limin Holdings, Taihe Co., and Jiangyin Sulin Chemical [14][21]. - The competitive landscape is characterized by a "three-legged" structure dominated by Limin, Sulin, and Jiangsu New River, with the top two companies holding over 80% of the market share [14][21]. Future Trends - The industry is expected to see continued consolidation, with leading companies enhancing their market position through economies of scale and technological barriers [21][22]. - Emerging markets, particularly in Southeast Asia and Brazil, are driving demand growth, prompting domestic companies to accelerate global expansion and establish partnerships with multinational agrochemical firms [22][23]. - The industry is shifting towards green transformation and high-end formulation research, with a focus on developing low-toxicity and low-residue products to meet stricter environmental standards [23].